International Journal of Hematology

, Volume 106, Issue 4, pp 508–516 | Cite as

Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

  • Tomás José González-López
  • Fernando Fernández-Fuertes
  • José Angel Hernández-Rivas
  • Blanca Sánchez-González
  • Violeta Martínez-Robles
  • María Teresa Alvarez-Román
  • Gloria Pérez-Rus
  • Cristina Pascual
  • Silvia Bernat
  • Esther Arrieta-Cerdán
  • Carlos Aguilar
  • Abelardo Bárez
  • María Jesús Peñarrubia
  • Pavel Olivera
  • Angeles Fernández-Rodríguez
  • Erik de Cabo
  • Luis Javier García-Frade
  • José Ramón González-Porras
Original Article


Eltrombopag is safe and effective in primary chronic ITP. However, lack of clinical trials avoids a clear demonstration of its utility in newly diagnosed and persistent ITP. Our aim here is to report Spanish results for this type of patients. We retrospectively evaluated 220 adult primary ITP patients. According to standard definition, patients were allocated to newly diagnosed (n = 30), persistent (n = 30), and chronic (n = 160) ITP. Groups were homogenous regarding most relevant parameters. 180 (90%) of 220 patients achieved a platelet response (R) with 167 (75.9%) complete responses (CR) after a 15-month follow-up. No statistical significant differences among groups but a trend towards a greater efficacy in newly diagnosed ITP were observed (93.3% of responses with 86.7% of CR). Efficacy in persistent ITP (83.3% of responses with 80.0% of CR) and chronic ITP (79.4% of responses with 73.1% of CR) was similar. 70 patients (31.8%) experienced adverse events. 15 of them were grade 3–4. Most common adverse effects were headache and hepatobiliary laboratory abnormalities (HBLAs). One persistent ITP had a venous thrombosis and one chronic ITP had grade II myelofibrosis. We consider Eltrombopag use for the early stage ITP as effective and safe as it is in chronic ITP.


Immune Thrombocytopenia ITP Thrombopoietin TPO 



We are grateful to Alicia García-García and Raquel Ranedo-Zaldo for their attention to some technical aspects.

Author contributions

Conception and design: TJGL and JRGP; data collection: all authors; statistical analysis: TJGL and JRGP; analysis and interpretation of results: all authors; writing article (text and tables): JRGP and TJGL; final approval of article: all authors.

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.

Supplementary material

12185_2017_2275_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 16 kb)


  1. 1.
    Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008.CrossRefPubMedGoogle Scholar
  2. 2.
    Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.CrossRefPubMedGoogle Scholar
  3. 3.
    Stasi R, Stipa E, Masi M, Cecconi M, Scimò MT, Oliva F, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98:436–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.CrossRefPubMedGoogle Scholar
  5. 5.
    Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004;83:764–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109:1401–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127:296–302.CrossRefPubMedGoogle Scholar
  9. 9.
    Cooper N, Woloski BM, Fodero EM, Novoa M, Leber M, Beer JH, Bussel JB. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood. 2002;99:1922–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Sailer T, Lechner K, Panzer S, Kyrle PA, Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica. 2006;91:1041–5.PubMedGoogle Scholar
  11. 11.
    Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–207.CrossRefPubMedGoogle Scholar
  12. 12.
    Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889–99.CrossRefPubMedGoogle Scholar
  13. 13.
    Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121:537–45.CrossRefPubMedGoogle Scholar
  14. 14.
    Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118:4338–45.CrossRefPubMedGoogle Scholar
  15. 15.
    Gonzalez-Lopez TJ, Alvarez-Roman MT, Pascual C, Sanchez-Gonzalez B, Fernandez-Fuentes F, Jarque I, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016;97:297–302.CrossRefPubMedGoogle Scholar
  16. 16.
    Tagariello G, Sartori R, Radossi P, Maschio N, Risato R, Stasi R. Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment. Br J Haematol. 2012;157:256–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Cantoni N, Heizmann M, Bargetzi M. Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment. Br J Haematol. 2012;157:639–41.CrossRefPubMedGoogle Scholar
  18. 18.
    Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, et al. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. Br J Haematol. 2012;158:798–800.CrossRefPubMedGoogle Scholar
  19. 19.
    Contis A, Lazaro E, Greib C, Pellegrin JL, Viallard JF. Romiplostim as early treatment for refractory primary immune thrombocytopenia. Int J Hematol. 2013;98:520–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Tripathi AK, Shukla A, Mishra S, Yadav YS, Yadav DK. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients. Int J Hematol. 2014;99:413–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol. 1999;107:716–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Godeau B, Chevret S, Varet B, Lefrère F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359:23–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Despotovic JM, Neunert CE. Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia? Hematol Am Soc Hematol Educ Program. 2013;2013(1):283–5.Google Scholar
  24. 24.
    Ghanima W, Khelif A, Waage A, Michel M, Tjonnfjord GE, Romdhan NB, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:1653–61.CrossRefPubMedGoogle Scholar
  25. 25.
    Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012;87:886–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989–95.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121:1976–81.CrossRefPubMedGoogle Scholar
  28. 28.
    Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115:2755–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90:494–500.CrossRefPubMedGoogle Scholar
  30. 30.
    Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99:1264–71.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Stirnemann J, Kaddouri N, Khellaf M, Morin AS, Prendki V, Michel M, et al. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2016;96:269–75.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang M, Liu YF, Sun H, Xie XS, Ma J, Gan SL. Clinical analysis of recombinant human thrombopoietin for treatment of 46 adult patients with newly diagnosed primary immune thrombocytopenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24:531–5.PubMedGoogle Scholar
  33. 33.
    Li Y, Huang Q, Wang C, Muhebaier, An L, Wang X. Efficacy and safety of high-dose dexamethasone combined with rhTPO for newly diagnosed adults with severe immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2016;37:134–7.PubMedGoogle Scholar
  34. 34.
    Newland A, Godeau B, Priego V, Viallard JF, Lopez Fernandez MF, Orejudos A, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172:262–73.CrossRefPubMedGoogle Scholar
  35. 35.
    Gomez-Almaguer D, Herrera-Rojas MA. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014;123:3906–8.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Tomás José González-López
    • 1
  • Fernando Fernández-Fuertes
    • 2
  • José Angel Hernández-Rivas
    • 3
  • Blanca Sánchez-González
    • 4
  • Violeta Martínez-Robles
    • 5
  • María Teresa Alvarez-Román
    • 6
  • Gloria Pérez-Rus
    • 7
  • Cristina Pascual
    • 7
  • Silvia Bernat
    • 8
  • Esther Arrieta-Cerdán
    • 9
  • Carlos Aguilar
    • 10
  • Abelardo Bárez
    • 11
  • María Jesús Peñarrubia
    • 12
  • Pavel Olivera
    • 13
  • Angeles Fernández-Rodríguez
    • 14
  • Erik de Cabo
    • 15
  • Luis Javier García-Frade
    • 16
  • José Ramón González-Porras
    • 17
  1. 1.Department of HematologyHospital Universitario de BurgosBurgosSpain
  2. 2.Department of HematologyHospital Universitario Insular de Gran CanariaLas Palmas De Gran CanariaSpain
  3. 3.Department of HematologyHospital Infanta LeonorMadridSpain
  4. 4.Department of HematologyHospital del MarBarcelonaSpain
  5. 5.Department of HematologyHospital de LeónLeónSpain
  6. 6.Department of HematologyHospital Universitario La PazMadridSpain
  7. 7.Department of HematologyHospital General Universitario Gregorio MarañónMadridSpain
  8. 8.Department of HematologyHospital de La PlanaCastellónSpain
  9. 9.Department of StatisticsHospital Universitario de BurgosBurgosSpain
  10. 10.Department of HematologyHospital de SoriaSoriaSpain
  11. 11.Department of HematologyHospital de AvilaAvilaSpain
  12. 12.Department of HematologyHospital Clínico de ValladolidValladolidSpain
  13. 13.Department of HematologyHospital Universitario Vall de HebronBarcelonaSpain
  14. 14.Department of HematologyHospital Universitario Central de AsturiasOviedoSpain
  15. 15.Department of HematologyHospital del BierzoPonferradaSpain
  16. 16.Department of HematologyHospital Universitario Río HortegaValladolidSpain
  17. 17.Department of HematologyIBSAL-Hospital Universitario de SalamancaSalamancaSpain

Personalised recommendations